Contribute Try STAT+ Today

A lymphoma drug that was approved later than expected by regulators is at the center of a lawsuit accusing Bristol Myers Squibb (BMY) of deliberately delaying production and development of the medicine in order to save $6.4 billion in payments to investors.

At issue is a provision in the 2019 agreement in which Bristol Myers paid $80.3 billion for Celgene. As part of the deal, Bristol Myers agreed to pay Celgene shareholders $9 in cash, or contingent value rights, for each share they held. But there was a stipulation — the company had to win Food and Drug Administration approval for a treatment for Non-Hodgkin’s lymphoma by Dec. 31, 2020.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment